Mirum Pharmaceuticals Q4 EPS $(0.99) Beats $(1.02) Estimate, Sales $27.91M Beat $24.57M Estimate

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 40 percent increase over losses of $(1.65) per share from the same period last year. The company reported quarterly sales of $27.91 million which beat the analyst consensus estimate of $24.57 million by 13.58 percent. This is a 789.29 percent increase over sales of $3.14 million the same period last year.